Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information click here
Template:DiseaseDisorder infobox
Overview
Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations.
Adjuvant therapies in children and adolescents
Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents [1] (DONOT EDIT)
“ |
The Role of Physical Activity in Management * From current pediatric data, it would appear that an exercise program should be included as part of a comprehensive risk factor modification program for the prevention of cardiovascular disease in children and adolescents. * Emphasis on regular physical activity rather than improvement in aerobic capacity appears to be the best approach for structuring such a program. * More long-term data are needed to completely assess the role of physical activity in risk factor modification for the pediatric population. Nonpharmacological Therapies * In general, dietary recommendations should be consistent with good nutrition, aimed at a proper caloric balance to ensure optimal growth and development while preventing obesity.
|
” |
References
- ↑ McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP; et al. (2007). "Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing". Circulation. 115 (14): 1948–67. doi:10.1161/CIRCULATIONAHA.107.181946. PMID 17377073.